You can buy or sell LGND and other stocks, options, ETFs, and crypto commission-free!
Ligand Pharmaceuticals Incorporated Common Stock, also called Ligand Pharmaceuticals, is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Read More The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Guru FocusMar 15
Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares
CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 03/13/2019 at an average price of $114.29 a share.
Yahoo FinanceMar 15
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
American International Group (AIG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive gr...
Simply Wall StMar 13
Should You Be Excited About Ligand Pharmaceuticals Incorporated’s (NASDAQ:LGND) 26% Return On Equity?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we’ll use ROE to better understand Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Over the last twelve months Ligand Pharmaceuticals has recorded a ROE of 26%. One way to conceptualize this, is that for each $1 of shareholders’ equity it has, the company made $0...
Expected May 7, After Hours